Search
Research
Tertiary prevention and treatment of rheumatic heart disease: a National Heart, Lung, and Blood Institute working group summaryAlthough entirely preventable, rheumatic heart disease, a disease of poverty and social disadvantage resulting in high morbidity and mortality, remains an ever-present burden in low-income and middle-income countries and rural, remote, marginalised and disenfranchised populations within high-income countries.
Research
Prospects for the future: supporting the elimination of rheumatic heart disease – a National Heart, Lung, and Blood Institute Workshop ProceedingsJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
News & Events
The Kids Research Institute Australia researchers awarded $11 million to support vital child health researchResearchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.
News & Events
Child health a focus in national research grantsThe Kids Research Institute Australia researchers have been awarded more than $8 million in prestigious project grants from the NHMRC.
News & Events
Community collaboration ensures ending RHD is everybody’s businessCollaboration is the driving force behind ‘END RHD Demonstration Communities’ – a new community-driven, research-backed approach to tackling rheumatic heart disease (RHD) in remote Australia.
News & Events
New coalition to end rheumatic heart disease once and for allSix leading health organisations have joined a new coalition to end rheumatic heart disease in Australia, disproportionately affecting Indigenous Australians.
News & Events
$2 million grant to develop diagnostic tool for rheumatic feverThe Kids Research Institute Australia & Menzies School of Health Research will lead an international project to develop a diagnostic tool for acute rheumatic fever.
Research
Missed Opportunities for Diagnosing Acute Rheumatic FeverWe have read with interest the new publication by Rouhiainen and colleagues on missed opportunities for preventing or diagnosing acute rheumatic fever (ARF).
Research
Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilisAlthough benzylpenicillin (penicillin G) is listed by the World Health Organization as an Essential Medicine, dose optimization is a persistent challenge, especially for long-acting intramuscular formulations. Maintaining sustained antibiotic exposure at target concentrations is crucial for secondary chemoprophylaxis of rheumatic heart disease and treatment of syphilis.
Research
Severe adverse reactions to benzathine penicillin G in rheumatic heart disease: A systematic review and meta-analysisFear of severe adverse reaction (SAR) and reluctance of health care providers to administer intramuscular injections are major contributing factors to poor adherence of benzathine penicillin G (BPG) in the management of rheumatic heart disease (RHD). However, data on the risk of SARs following BPG injections for RHD are relatively limited and inconclusive. Our systematic review and meta-analysis aimed to evaluate the incidence of SARs associated with BPG injections used for secondary prophylaxis of RHD.